Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | PEPD | P12955 | 2/20 | 0.46 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14202917 | 1.00 | KLK5 (0.51) | KLK5PEPDXPNPEP1FKBP1AELANE | |
| SCHEMBL12055223 | 0.91 | PEPD (0.49) | KLK5PEPDXPNPEP1FKBP1AELANE | |
| SCHEMBL806133 | 0.89 | ACE (0.51) | PEPDELANEACECMA1 | |
| SCHEMBL159043 | 0.89 | ACE (0.51) | PEPDELANEACECMA1 | |
| SCHEMBL1300341 | 0.89 | ACE (0.51) | PEPDELANEACECMA1 | |
| SCHEMBL26121717 | 0.89 | ACE (0.51) | PEPDELANEACECMA1 | |
| SCHEMBL8055611 | 0.88 | ELANE (0.42) | KLK5ELANEACECMA1 | |
| SCHEMBL14232792 | 0.88 | ELANE (0.42) | KLK5ELANEACECMA1 | |
| SCHEMBL806180 | 0.88 | ELANE (0.42) | KLK5ELANEACECMA1 | |
| SCHEMBL17348390 | 0.87 | KLK5 (0.53) | KLK5PEPDXPNPEP1FKBP1AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| WO-2021018118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | WO | disclosed |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC (US) | 2014-05-08 | — | — | US | disclosed |
| US-8642554-B2 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642554-B2 | Smac mimetic dimers and trimers useful as anti-cancer agents | JOYANT PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2012037259-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20090202486-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| WO-2009079352-A1 | MACROCYCLIC OXIMYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090104151-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090104151-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005051410-A9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202486-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | CTSC, DPP4, DNPEP | KLK5 820/4885PEPD 7/4885XPNPEP1 68/4885 |
| US-20090104151-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | BID, BAD, BIRC3 | KLK5 3968/4885PEPD 3909/4885XPNPEP1 2855/4885 |
| US-20140127155-A1 | Smac mimetic dimers and trimers useful as anti-cancer agents | BID, BAD, BIRC3 | KLK5 3968/4885PEPD 3909/4885XPNPEP1 2855/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | KLK5 1470/4885PEPD 38/4885XPNPEP1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.